iShares Russell 2000 ETF vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? iShares Russell 2000 ETF trades at $278.66 (market cap $77.70B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.33 (market cap $2.27B). The key difference: iShares Russell 2000 ETF is far larger — about 34.2× SELLAS Life Sciences Group Inc. Common Stock's market cap, and iShares Russell 2000 ETF is more actively traded (35,598,983 versus 4,179,659). Which is the better fit depends on your goals.
| IWM | SLS | |
|---|---|---|
Market Cap | $77.70B | $2.27B |
Volume | 35,598,983 | 4,179,659 |
52-Week High | $305.06 | $15.46 |
52-Week Low | $229.13 | $1.39 |
Typical Hold Time | 83 Days | — |
Sector | — | Health |
Enterprise Value | — | $2.14B |
Signals from Pluang's Aura AI — not financial advice
IWM trades at $277.72, down 1.27% amid broader small-cap weakness. Technical indicators show a bearish trend with resistance at $278 and support at $275. The ETF faces headwinds from Federal Reserve rate hikes and underperformance relative to large-cap indices over the past decade. Recent news highlights concerns about small-cap risk premiums and competition from more selective small-cap funds.
The outlook remains cautious as rising interest rates pressure small-cap valuations. Opportunities exist for long-term investors seeking diversification from tech-heavy large caps, but near-term risks include economic sensitivity and narrow market breadth. The bearish technical setup suggests further downside potential unless macroeconomic conditions improve.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →